US-based Edwards Lifesciences has obtained clearance from the US Food and Drug Administration (FDA) for its hemodynamic monitoring platform, HemoSphere.

The advanced platform is designed to enable timely decisions by providing clarity to clinicians on the hemodynamics or the blood flow factors of a patient.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is claimed that the scalable monitoring platform can be customised according to the requirements of each patient and clinician.

Edwards Lifesciences critical care corporate vice-president Catherine Szyman said: "The HemoSphere advanced monitor builds on Edwards' more than 50 years of experience in providing clinicians with technology and education to help improve patient care and lays the foundation for future advancements in hemodynamic monitoring."

The platform's wireless advanced monitor can be used to collect and evaluate the hemodynamic data of a patient and is compatible with the Edwards Swan-Ganz pulmonary artery catheter and oximetry catheters.

See Also:

"Clinicians can choose the clinical support screens that best suit their needs and monitor the pressures and blood flow of the heart as conditions change, informing potentially life-saving decisions on behalf of their patients."

Loma Linda University Medical Center clinical research and perioperative ultrasound director Davinder Ramsingh said: "The HemoSphere advanced monitor enables simplified visual clinical support, which is particularly important in the care of our most complex, critically ill patients.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

"Clinicians can choose the clinical support screens that best suit their needs and monitor the pressures and blood flow of the heart as conditions change, informing potentially life-saving decisions on behalf of their patients."

HemoSphere also features visual clinical support screens and an intuitive touchscreen that allow clinicians to tailor the platform according to the needs of their care environment.

The HemoSphere advanced monitor has been approved for commercialisation in Europe, Japan, Australia and New Zealand.